clinical efficacy – mycolab.ai

Multidisciplinary Integrative Medicine Approach for Cancer Patients: A Multicenter Retrospective Study

mycolabadmin

This study shows that when cancer patients use complementary treatments like mushroom supplements, vitamins, and probiotics alongside their cancer medications under doctor supervision, they experience fewer side effects and better quality of life. Almost 93% of patients had no side effects from these supplements, and many reported less fatigue and better overall wellness. The key finding is that patients should work with their medical team rather than self-prescribing these treatments to avoid dangerous interactions.

If psychedelics heal, how do they do it?

mycolabadmin

Psychedelic drugs like MDMA and magic mushrooms are showing remarkable promise in treating serious mental health conditions like PTSD and depression, with clinical trials demonstrating higher success rates than traditional therapy alone. However, scientists still don’t fully understand how these drugs work at the molecular and brain level, or whether the hallucinations they produce are necessary for healing. Researchers are investigating whether modified versions without hallucinations could provide the same benefits while being easier to administer, while also exploring how individual factors and treatment environment affect outcomes.

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review

mycolabadmin

This review examines two emerging psychiatric treatments—ketamine and psilocybin—for treating hard-to-treat mental health conditions in children and teenagers. Both work by affecting brain chemicals differently than traditional medications and can provide rapid symptom relief, sometimes within hours or days rather than weeks. The study found promising results for depression, anxiety, PTSD, and bipolar disorder, though researchers emphasize that more studies are needed to ensure these treatments are safe for developing brains and that careful ethical guidelines must be established.

Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis

mycolabadmin

This comprehensive analysis of 10 clinical trials shows that psilocybin, a compound from magic mushrooms, can rapidly reduce depression symptoms starting within one day of administration and maintain these benefits for up to 6 months. Higher doses and two treatment sessions produced better results than single lower doses. While psilocybin did raise blood pressure temporarily, it was generally well-tolerated with dropout rates similar to placebo.

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials

mycolabadmin

This systematic review examines how psychedelic-assisted therapies like ketamine and psilocybin help people with severe, treatment-resistant depression that doesn’t respond to standard antidepressants. The analysis of 10 recent clinical trials shows these therapies work quickly, often providing symptom relief within days rather than weeks, and importantly, they also help people return to work and daily functioning. These treatments are generally well-tolerated with minimal cognitive side effects, suggesting they could become important new options for patients who haven’t benefited from conventional depression treatments.

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews

mycolabadmin

This research review examines how psychedelic drugs like psilocybin and ketamine might help treat addiction. Studies show these substances could help people quit alcohol, drugs, and smoking by reducing cravings and promoting long-term abstinence. While results are promising, scientists caution that more rigorous research is needed before these treatments can be recommended for regular medical use, and they acknowledge real risks associated with these powerful drugs.

Psychedelics and Suicide-Related Outcomes: A Systematic Review

mycolabadmin

This comprehensive review examined how psychedelic substances like psilocybin and MDMA affect suicidal thoughts. Overall, psilocybin and MDMA-assisted therapy showed promise in reducing suicidal ideation in controlled clinical settings, with effects appearing within weeks. However, LSD use was associated with increased suicidal thoughts. The researchers conclude that while psychedelics show potential, more research is needed to ensure safety and understand how they work.

Antifungal Efficacy of Ganoderma lucidum and Clotrimazole for Treatment of Denture Stomatitis: A Randomized Clinical Trial

mycolabadmin

This study tested whether Ganoderma lucidum, a medicinal mushroom used in traditional Asian medicine, could treat denture stomatitis as effectively as the standard treatment clotrimazole. Both treatments reduced pain and improved symptoms equally well over two weeks. The results suggest that Ganoderma lucidum could be a useful alternative for patients who don’t respond well to standard antifungal drugs.

A systematic review to assess the use of psilocybin in the treatment of headaches

mycolabadmin

Researchers reviewed eight studies examining whether psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, could treat various types of headaches and migraines. Most studies found that psilocybin provided clinically significant relief, with participants experiencing improvements in how often they got headaches, how intense they were, and how long they lasted. However, some users experienced side effects like hallucinations or temporary increases in anxiety, and the compound remains illegal in most countries, limiting current research.

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

mycolabadmin

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Research Keyword: clinical efficacy